Literature DB >> 34014298

Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.

Kathryn Corbett1, Alisha Sharma2, Gregory R Pond3, Priscilla K Brastianos4,5, Sunit Das1,6, Arjun Sahgal7, Katarzyna J Jerzak1,8.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34014298      PMCID： PMC8138748          DOI： 10.1001/jamaoncol.2021.1359

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

Review 1.  Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Authors:  G Nader-Marta; D Martins-Branco; E Agostinetto; M Bruzzone; M Ceppi; L Danielli; M Lambertini; N Kotecki; A Awada; E de Azambuja
Journal:  ESMO Open       Date:  2022-05-30

2.  Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.

Authors:  Mei-Mei Zheng; Yang-Si Li; Hai-Yan Tu; Hao Sun; Kai Yin; Ben-Yuan Jiang; Jin-Ji Yang; Xu-Chao Zhang; Qing Zhou; Chong-Rui Xu; Zhen Wang; Hua-Jun Chen; De-Xiang Zhou; Yi-Long Wu
Journal:  BMC Med       Date:  2022-05-30       Impact factor: 11.150

3.  Modifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors.

Authors:  Michael Chuwei Jin; Gary Hsin; John Ratliff; Reena Thomas; Corinna Clio Zygourakis; Gordon Li; Adela Wu
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

4.  Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study.

Authors:  Yizhuo Kelly Gao; Markus Kuksis; Badr Id Said; Rania Chehade; Alex Kiss; William Tran; Faisal Sickandar; Arjun Sahgal; Ellen Warner; Hany Soliman; Katarzyna J Jerzak
Journal:  Oncologist       Date:  2021-09-21

Review 5.  Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.

Authors:  Ilana Schlam; Margaret E Gatti-Mays
Journal:  Oncologist       Date:  2022-07-05       Impact factor: 5.837

6.  Karnofsky Performance Status (KPS) ≤60 Is Strongly Associated With Shorter Brain-Specific Progression-Free Survival Among Patients With Metastatic Breast Cancer With Brain Metastases.

Authors:  Mark Freeman; Marguerite Ennis; Katarzyna J Jerzak
Journal:  Front Oncol       Date:  2022-07-27       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.